ATN Pro Members Get the Playbook.
Member Q&A: Cutting acquisition costs with Jonathan Geller. Nov. 17.
The product would effectively function as an “electronic version of GLP-1” obesity drugs, founding partner Nyx He said
A recent survey found that patient satisfaction with GLP-1 treatment dropped significantly once off the medications, with a high likelihood of regaining weight. Experts point to maintaining treatment and exercising as key preventive factors
While weight reduction is an important outcome, it is only one measure of progress. Long-term health depends on much more than the number on the scale.
New research shows GLP-1 users are shelling out roughly $449 a month on fitness amid broader lifestyle shifts, although the general consensus is conflicted on whether weight-loss drugs are a net benefit for the fitness and wellness industry
In a new study, waist circumference proved a better predictor of mortality than BMI among older adults, supporting a broader shift in fitness from tracking scale weight to measuring fat, muscle and metabolic health
The focus of the partnership has shifted to whether solutions targeting the microbiome can deliver benefits alongside GLP-1-based medicines
Nestle believes the drugs are also creating a new market for products designed to address the side effects of rapid weight loss
Gyms are evolving to keep up with climbing GLP-1 adoption, offering muscle-preservation workouts, telehealth partnerships and integrated wellness services
More than 25% of GLP-1 users in the U.K. reported increasing fitness spending after starting treatment. Those results are promising, but other data shows it's far from a given that weight-loss drugs will prove to be a net benefit for the industry
Fitbit data from 750 adults found that daily movement and exercise levels declined after people started taking GLP-1 weight-loss drugs.
Sign Up to Our Newsletter
